Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Bipolar Disorder (Manic Depression) - Pipeline Review, H1 2015', provides an overview of the Bipolar Disorder (Manic Depression)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bipolar Disorder (Manic Depression) Overview 10
Therapeutics Development 11
Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11
Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12
Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13
Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 15
Bipolar Disorder (Manic Depression) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bipolar Disorder (Manic Depression) - Products under Development by Companies 19
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 22
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 23
Ascendis Pharma A/S 23
AstraZeneca PLC 24
Convergence Pharmaceuticals Ltd. 25
D-Pharm Ltd. 26
Delpor, Inc. 27
Eli Lilly and Company 28
Intas Pharmaceuticals Ltd. 29
Intra-Cellular Therapies, Inc. 30
KemPharm, Inc. 31
MarcoPolo Pharmaceuticals SA 32
Navigen Pharmaceuticals, Inc. 33
Neurocrine Biosciences, Inc. 34
Omeros Corporation 35
Otsuka Holdings Co., Ltd. 36
Pfizer Inc. 37
Reviva Pharmaceuticals Inc. 38
Richter Gedeon Nyrt. 39
SK Biopharmaceuticals Co., Ltd. 40
Sumitomo Dainippon Pharma Co., Ltd. 41
Takeda Pharmaceutical Company Limited 42
Teva Pharmaceutical Industries Limited 43
Zogenix, Inc. 44
Zysis Limited 45
Bipolar Disorder (Manic Depression) - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Target 47
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
ACP-005 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
aripiprazole - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
aripiprazole - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
aripiprazole CR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BRDK-98958073 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
cariprazine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CNV-1061436 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DP-VPA - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drug for Bipolar Disorder - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Drug for Cancer and Neurodegenerative Disease - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Endoxifen - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ITI-007 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
KP-303 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
lurasidone hydrochloride - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
LY-2979165 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NP-202 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
paliperidone palmitate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PGW-5 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
quetiapine fumarate ER - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ramelteon - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
risperidone - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
risperidone - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RP-5063 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
SKL-PSY - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule to Inhibit VMAT-2 for Schizophrenia, Bipolar Disorder and Movement Disorders - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
uridine triacetate - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
ziprasidone hydrochloride - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Bipolar Disorder (Manic Depression) - Recent Pipeline Updates 94
Bipolar Disorder (Manic Depression) - Dormant Projects 113
Bipolar Disorder (Manic Depression) - Dormant Projects 113
Bipolar Disorder (Manic Depression) - Discontinued Products 116
Bipolar Disorder (Manic Depression) - Product Development Milestones 117
Featured News & Press Releases 117
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole 117
Mar 30, 2015: Sunovion Pharmaceuticals Europe to Present New Data on LATUDA (lurasidone) at the 23rd European Congress of Psychiatry 117
Jan 14, 2015: Sunovion Pharmaceuticals Files Patent Infringement Lawsuits Regarding Latuda 118
Jan 13, 2015: Germany's Federal Court Invalidates AstraZeneca's Patent On Seroquel XR 119
Apr 03, 2014: Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression 119
Mar 31, 2014: Forest Laboratories and Gedeon Richter Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression 119
Nov 13, 2013: Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly 121
Nov 01, 2013: Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry 121
Oct 29, 2013: A Phase I ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidates 123
Jun 28, 2013: Sunovion Pharmaceuticals Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression 124
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for Bipolar Disorder (Manic Depression), H1 2015 11
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Development by Companies, H1 2015 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Bipolar Disorder (Manic Depression) - Pipeline by Ascendis Pharma A/S, H1 2015 23
Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca PLC, H1 2015 24
Bipolar Disorder (Manic Depression) - Pipeline by Convergence Pharmaceuticals Ltd., H1 2015 25
Bipolar Disorder (Manic Depression) - Pipeline by D-Pharm Ltd., H1 2015 26
Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H1 2015 27
Bipolar Disorder (Manic Depression) - Pipeline by Eli Lilly and Company, H1 2015 28
Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H1 2015 29
Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H1 2015 30
Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H1 2015 31
Bipolar Disorder (Manic Depression) - Pipeline by MarcoPolo Pharmaceuticals SA, H1 2015 32
Bipolar Disorder (Manic Depression) - Pipeline by Navigen Pharmaceuticals, Inc., H1 2015 33
Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences, Inc., H1 2015 34
Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H1 2015 35
Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 36
Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H1 2015 37
Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H1 2015 38
Bipolar Disorder (Manic Depression) - Pipeline by Richter Gedeon Nyrt., H1 2015 39
Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 40
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 41
Bipolar Disorder (Manic Depression) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 42
Bipolar Disorder (Manic Depression) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 43
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H1 2015 44
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H1 2015 45
Assessment by Monotherapy Products, H1 2015 46
Number of Products by Stage and Target, H1 2015 48
Number of Products by Stage and Mechanism of Action, H1 2015 50
Number of Products by Stage and Route of Administration, H1 2015 52
Number of Products by Stage and Molecule Type, H1 2015 54
Bipolar Disorder (Manic Depression) Therapeutics - Recent Pipeline Updates, H1 2015 94
Bipolar Disorder (Manic Depression) - Dormant Projects, H1 2015 113
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H1 2015 114
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H1 2015 115
Bipolar Disorder (Manic Depression) - Discontinued Products, H1 2015 116